1. Home
  2. NRIX vs INMD Comparison

NRIX vs INMD Comparison

Compare NRIX & INMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NRIX
  • INMD
  • Stock Information
  • Founded
  • NRIX 2009
  • INMD 2008
  • Country
  • NRIX United States
  • INMD Israel
  • Employees
  • NRIX N/A
  • INMD N/A
  • Industry
  • NRIX Biotechnology: Pharmaceutical Preparations
  • INMD Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • NRIX Health Care
  • INMD Health Care
  • Exchange
  • NRIX Nasdaq
  • INMD Nasdaq
  • Market Cap
  • NRIX 970.1M
  • INMD 887.0M
  • IPO Year
  • NRIX 2020
  • INMD 2019
  • Fundamental
  • Price
  • NRIX $11.64
  • INMD $14.63
  • Analyst Decision
  • NRIX Strong Buy
  • INMD Hold
  • Analyst Count
  • NRIX 16
  • INMD 6
  • Target Price
  • NRIX $29.56
  • INMD $17.56
  • AVG Volume (30 Days)
  • NRIX 978.7K
  • INMD 1.7M
  • Earning Date
  • NRIX 07-09-2025
  • INMD 07-30-2025
  • Dividend Yield
  • NRIX N/A
  • INMD N/A
  • EPS Growth
  • NRIX N/A
  • INMD 8.69
  • EPS
  • NRIX N/A
  • INMD 2.29
  • Revenue
  • NRIX $88,381,000.00
  • INMD $392,408,000.00
  • Revenue This Year
  • NRIX $34.87
  • INMD $0.16
  • Revenue Next Year
  • NRIX N/A
  • INMD $4.84
  • P/E Ratio
  • NRIX N/A
  • INMD $6.34
  • Revenue Growth
  • NRIX 41.86
  • INMD N/A
  • 52 Week Low
  • NRIX $8.18
  • INMD $13.14
  • 52 Week High
  • NRIX $29.56
  • INMD $19.85
  • Technical
  • Relative Strength Index (RSI)
  • NRIX 46.20
  • INMD 50.91
  • Support Level
  • NRIX $11.13
  • INMD $13.86
  • Resistance Level
  • NRIX $11.92
  • INMD $14.93
  • Average True Range (ATR)
  • NRIX 0.77
  • INMD 0.44
  • MACD
  • NRIX -0.15
  • INMD -0.02
  • Stochastic Oscillator
  • NRIX 11.79
  • INMD 37.85

About NRIX Nurix Therapeutics Inc. Common stock

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

About INMD InMode Ltd.

InMode Ltd provides minimally and non-invasive surgical aesthetic and medical treatment solutions in the United States. Its products and solutions address three energy-based treatment categories that include face & body contouring, medical aesthetics, and women's health. InMode has developed products using its technology for plastic surgery, dermatology, gynecology, and ophthalmology. Its product platforms include BodyTite, Optimas, Votiva, Contoura, Triton, EmbraceRF, EvolveX, Evoke, EmpowerRF and Morpheus8. The majority of its revenue comes from the United States.

Share on Social Networks: